Companies: 10,795·Total market cap: $144.5T
Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAMNASDAQHealthcare● Active
$29.78
+$0.38(+1.29%)
Market Cap$3.1B
P/E Ratio—
52W High$36.44
52W Low$15.6
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Beam Therapeutics Inc. (BEAM) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BEAM · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.64beam eps ttm · beam earnings per shareEarnings history
PE Ratio (TTM)—beam pe ratio ttm · beam price to earningsPE Ratio deep dive
Revenue (TTM)$164.0Mbeam revenue ttm · beam annual revenueFull revenue history
Dividend Yield4.80%does beam pay dividends · beam dividend yieldDividend history
Shares Outstanding98.9Mbeam shares outstanding · beam floatShares outstanding history
Next EarningsAug 4, 2026Est.beam earnings date · beam next earningsEarnings history

Explore Beam Therapeutics Inc. Data

beam stock data · financials
Market Cap$3.1Bbeam market cap · beam valuation
Analyst Forecast$48 · Buy
Dividends4.80%does beam therapeutics inc. pay dividends · beam dividend yield
Revenue$139.7M+120.01%beam therapeutics inc. annual revenue · beam revenue
EarningsEPS $-0.81+82.31%beam earnings · beam eps
PE Ratio—beam pe ratio · beam price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$139.7M▲ +120.01% YoY
202320242025
beam therapeutics inc. revenue · beam revenue 2025
FY 2025Net Income-$80.0M▲ +78.77% YoY
202320242025
beam therapeutics inc. net income · beam profit 2025
FY 2025EPS$-0.81▲ +82.31% YoY
202320242025
beam eps · beam therapeutics inc. earnings per share 2025
TTM:Revenue: $164.0MNet Income: -$65.0MEPS: $-0.64View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy27 analystsis beam a buy · beam analyst rating
Strong Buy
0
Buy
18
Hold
8
Sell
1
Strong Sell
0
12-Month Price Target
$26.00Low
$29.78Current
$48.00Avg Target61.18% upside
$80.00High
beam price target · beam 12 month forecast

Total: 27 · Buy rate: 66.7%

The BEAM analyst consensus is Buy, based on ratings from 27 Wall Street analysts over the past 3 months. The average 12-month price target is $48.00, representing +61.18% upside from the current price of $29.78.

Stock Performance

Full History
1D-10.48%
1W+2.40%
1M-9.03%
3M+10.78%
YTD+6.06%
1Y+61.81%
5Y-65.65%

About Beam Therapeutics Inc.

CEOJohn Evans
IPO DateFeb 6, 2020
Employees393
CountryUS
Websitebeamtx.com

Beam Therapeutics Inc. founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle…

BiotechnologyHealthcareNASDAQUS

what is beam therapeutics inc. · beam stock overview · beam therapeutics inc. company profile · who is beam therapeutics inc. ceo · beam NASDAQ · beam therapeutics inc. headquarters · beam therapeutics inc. business segments

About Stock Overview & Key Data

Beam Therapeutics Inc. (BEAM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 6, 2020. As of the latest trading session, BEAM stock price is $29.78, with a market capitalization of $3.1B. The stock has returned +61.81% over the past 12 months and +6.06% year-to-date.

According to 27 Wall Street analysts, the consensus rating for Beam Therapeutics Inc. stock is Buy, with an average 12-month price target of $48.00. In fiscal year 2025, Beam Therapeutics Inc. reported revenue of $139.7M and net income of -$80.0M. For detailed data — including Beam Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Beam Therapeutics Inc. (BEAM) stock price is $29.78. The stock is traded on NASDAQ under the ticker symbol BEAM. The 52-week range is $15.60 – $36.44.

BEAM stock priceBEAM quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice